Misplaced Pages

Telmisartan/hydrochlorothiazide

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Telmisartan/hydrochlorothiazide
Combination of
TelmisartanAngiotensin II receptor antagonist
HydrochlorothiazideThiazide diuretic
Clinical data
Trade namesMicardisPlus, Micardis HCT, PritorPlus, others
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC40H38ClN7O6S2
Molar mass812.36 g·mol
3D model (JSmol)
SMILES
  • CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C.C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl
InChI
  • InChI=1S/C33H30N4O2.C7H8ClN3O4S2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39;8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39);1-2,10-11H,3H2,(H2,9,12,13)
  • Key:OZCVMXDGSSXWFT-UHFFFAOYSA-N
  (verify)

Telmisartan/hydrochlorothiazide, sold under the brand name Micardis HCT among others, is a fixed-dose combination medication used to treat high blood pressure. It is a combination of telmisartan an angiotensin II receptor antagonist with hydrochlorothiazide a diuretic. It may be used if telmisartan by itself is not sufficient. It is taken by mouth.

Common side effects include dizziness, upper respiratory tract infections, nausea, diarrhea, and tiredness. Severe side effects may include kidney problems, electrolyte problems, and allergic reactions. Use during pregnancy may harm the baby. Telmisartan works by blocking the effects of angiotensin II while hydrochlorothiazide works by decreasing the kidneys' ability to retain water.

The combination was approved for medical use in the United States in November 2000, and in the European Union in April 2002. The combination is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.

References

  1. "MicardisPlus 40 mg/12.5 mg Tablets - Summary of Product Characteristics (SmPC)". (emc). 28 May 2020. Retrieved 23 November 2020.
  2. ^ "Micardis HCT- telmisartan and hydrochlorothiazide tablet". DailyMed. 27 August 2020. Retrieved 4 October 2020.
  3. ^ "MicardisPlus EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 4 October 2020.
  4. ^ "PritorPlus EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 4 October 2020.
  5. ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 178. ISBN 9780857113382.
  6. "Drug Approval Package: Micardis HCT (telmisartan/hydrochlorothiazide) NDA #021162". U.S. Food and Drug Administration (FDA). 11 March 2004. Retrieved 4 October 2020.
  7. "Hydrochlorothiazide and telmisartan Uses, Side Effects & Warnings". Drugs.com. Retrieved 29 October 2019.
  8. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
Antihypertensive drugs acting on the renin–angiotensin system (C09)
ACE inhibitors
("-pril")
AIIRAs
("-sartan")
Renin inhibitors
("-kiren")
Dual ACE/NEP inhibitors
Neprilysin inhibitors
Other
Portal: Categories:
Telmisartan/hydrochlorothiazide Add topic